AudioCure Pharma specializes in the preclinical and clinical development of small molecules for the treatment of audiological and neurodegenerative diseases like sudden hearing loss, tinnitus, Parkinson’s and Alzheimer’s disease. In a first step the company focuses on sudden hearing loss.
Our compounds AC102 and AC002 have shown excellent efficacy in different animal models for the above-mentioned indications. Consequently, AudioCure is on its way to perform formal preclinical tests and to move AC102 into first-in-man testing.
Prof. Dr. Hans Rommelspacher, CSO
Dr. Reimar Schlingensiepen, CEO
AudioCure Pharma GmbH secures funding of about EUR 9 million for the further development of their lead candidate, AC102, in hearing loss
High-Tech Gründerfonds and Business Angel Invest in AudioCure Pharma GmbH Drug Development